Allogene Therapeutics, Inc. Forecast, price target & analysts
Allogene Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Allogene Therapeutics, Inc. Classifications & Recommendation:
Allogene Therapeutics, Inc. Price Target
| Target Price | $9.25 |
| Price | $1.38 |
| Potential |
570.29%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Allogene Therapeutics, Inc. 2026 .
The average Allogene Therapeutics, Inc. target price is $9.25.
This is
570.29%
register free of charge
$14.00
914.49%
register free of charge
$3.00
117.39%
register free of charge
|
|
| A rating was issued by 16 analysts: 14 Analysts recommend Allogene Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Allogene Therapeutics, Inc. stock has an average upside potential 2026 of
570.29%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.02 | 0.01 |
| 80.00% | 35.50% | |
| EBITDA Margin | -1,219,200.00% | -1,892,057.27% |
| 306.01% | 55.19% | |
| Net Margin | -1,400,586.00% | -1,963,070.42% |
| 215.79% | 40.16% |
14 Analysts have issued a sales forecast Allogene Therapeutics, Inc. 2025 . The average Allogene Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Allogene Therapeutics, Inc. EBITDA forecast 2025. The average Allogene Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Allogene Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Allogene Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.32 | -1.19 |
| 36.84% | 9.85% | |
| P/E | negative | |
| EV/Sales | 7,630.86 |
7 Analysts have issued a Allogene Therapeutics, Inc. forecast for earnings per share. The average Allogene Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Allogene Therapeutics, Inc....
Current Allogene Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 30 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 14 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 08 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 30 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
